Celgene Corporation (NASDAQ:CELG) just released results from a phase 3, randomized, double-blind, international clinical REMARC study to investigate its pipeline drug Revlimid against a …
At the 14th International Symposium on MPS and Related Diseases, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) presented positive pivotal Phase 3 trial of recombinant human …
Cowen’s healthcare analyst Eric Schmidt weighed in today with a few insights on Radius Health Inc (NASDAQ:RDUS), following a meeting with CEO Bob Ward and members of …
In a research report released today, Cowen analyst Eric Schmidt reiterated an Outperform rating on shares of Exelixis Inc. (NASDAQ:EXEL), following Friday’s news that …
In a research report published today, Cowen analyst Eric Schmidt reiterated an Outperform rating on shares of Incyte Corporation (NASDAQ:INCY), after the company and partner Merck filed an …
Cowen’s healthcare analyst Eric Schmidt came out today with a research note on Blueprint Medicines Corp (NASDAQ:BPMC), after the company announced that the FDA accepted the Company’s Investigational …
In a research report issued today, Cowen & Co. analyst Eric Schmidt reiterated an Outperform rating on Incyte Corporation (NASDAQ:INCY), while no price target …
Biogen Idec Inc (NASDAQ: BIIB) presented test results for BIIB037, a drug intended to treat Alzheimer’s disease, on March 20. The medical community …
Cowen’s healthcare analyst Eric Schmidt weighed in today with his thoughts on Exelixis, Inc. (NASDAQ:EXEL), after the company reported its fourth-quarter results and business update.
Cowen’s healthcare analyst Eric Schmidt is weighing in with some thoughts on BIND Therapeutics (NASDAQ:BIND), as the company yesterday announced an upbeat strategic overview for 2015, along with …
